326 related articles for article (PubMed ID: 34804076)
1. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
[TBL] [Abstract][Full Text] [Related]
3. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells for osteosarcoma.
Tarek N; Lee DA
Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Immunotherapy for Osteosarcoma.
Tullius BP; Setty BA; Lee DA
Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.
Pahl JH; Ruslan SE; Kwappenberg KM; van Ostaijen-Ten Dam MM; van Tol MJ; Lankester AC; Schilham MW
Cancer Immunol Immunother; 2013 Jul; 62(7):1235-47. PubMed ID: 23624801
[TBL] [Abstract][Full Text] [Related]
9. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.
Merchant MS; Bernstein D; Amoako M; Baird K; Fleisher TA; Morre M; Steinberg SM; Sabatino M; Stroncek DF; Venkatasan AM; Wood BJ; Wright M; Zhang H; Mackall CL
Clin Cancer Res; 2016 Jul; 22(13):3182-91. PubMed ID: 26823601
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
Buddingh EP; Schilham MW; Ruslan SE; Berghuis D; Szuhai K; Suurmond J; Taminiau AH; Gelderblom H; Egeler RM; Serra M; Hogendoorn PC; Lankester AC
Cancer Immunol Immunother; 2011 Apr; 60(4):575-86. PubMed ID: 21240486
[TBL] [Abstract][Full Text] [Related]
12. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target.
Zhu Y; Huang B; Shi J
Oncotarget; 2016 Jul; 7(30):47163-47172. PubMed ID: 27323411
[TBL] [Abstract][Full Text] [Related]
14. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
15. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
16. Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M; Bueno D; González-Navarro P; Brito A; Fernández L; Escudero A; Valentín J; Mestre-Durán C; Arranz-Álvarez M; Pérez de Diego R; Mendiola M; Pozo-Kreilinger JJ; Pérez-Martínez A
Front Immunol; 2019; 10():1814. PubMed ID: 31428099
[TBL] [Abstract][Full Text] [Related]
17. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
18. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
19. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
Quamine AE; Olsen MR; Cho MM; Capitini CM
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199783
[TBL] [Abstract][Full Text] [Related]
20. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity.
Johann PD; Vaegler M; Gieseke F; Mang P; Armeanu-Ebinger S; Kluba T; Handgretinger R; Müller I
BMC Cancer; 2010 Sep; 10():501. PubMed ID: 20858262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
